Substituted arylcyclopentenes as therapeutic agents

Patent metadata

Field	Value
Publication number	US-9796696-B2
Application number	US-201615088964-A
Country	US
Kind code	B2
Filing date	Apr 1, 2016
Priority date	Jan 25, 2007
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

Disclosed herein is a compound of the formula

Therapeutic methods, compositions, and medicaments, related thereto are also disclosed.

First claim

What is claimed is:

1. A compound of Formula I or II:

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen, C 1 to C 3 alkyl, or CH 2 CH 2 OH; and
R 2 is hydrogen, halogen, CH 2 OH, CH 3 , or CN.

2. The compound according to claim 1 , wherein the compound is a compound of the formula:

or a pharmaceutically acceptable salt thereof.

3. A composition comprising a compound according to claim 1 , wherein said composition is a liquid which is ophthalmically acceptable.

4. A method for treating glaucoma or ocular hypertension comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 .

5. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

6. A composition comprising a compound according to claim 5 , wherein said composition is a liquid which is ophthalmically acceptable.

7. A method for treating glaucoma or ocular hypertension comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 5 .

Assignees

• Allergan Inc

Inventors

• Donde Yariv
• Nguyen Jeremiah H

Classifications

• C07C65/19

  having unsaturation outside the aromatic ring · CPC title

• C07D409/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D213/55

  Acids; Esters · CPC title

• C07D307/68

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

• C07C323/52

  the carbon skeleton being acyclic and saturated · CPC title